Clinical Trials

314 enrolled

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT06325683 2026-05-26

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Phase 2 Suspended

184 enrolled

CNS

Glioblastoma

NCT03258567 2026-05-22

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

40 enrolled

Lymphoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

BreastEndocrineGynecologicHead & NeckSarcoma

30 enrolled

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT03527108 2026-05-22

Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC

36 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03646461 2026-05-22

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

Phase 2 Terminated

5 enrolled 9 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04503694 2026-05-22

REGINA

72 enrolled

Rectal Neoplasms

NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

EndocrineGenitourinaryNET

111 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

NCT06812858 2026-05-22

PD-1 Inhibitors Maintenance for cHL Post-autoHCT

83 enrolled

Phase 2 Not yet recruiting

Hodgkin Disease

NCT07355205 2026-05-22

FLINN

26 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07603856 2026-05-22

REVIVE

39 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04015778 2026-05-20

A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China

316 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04123379 2026-05-20

Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

Phase 2 Completed

48 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular

NCT06053658 2026-05-20

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

48 enrolled

Carcinoma, Renal Cell

NCT07013565 2026-05-20

ACCELERATE

20 enrolled

Phase 2 Not yet recruiting

Lymphoma, Large-Cell, Anaplastic

NCT07551583 2026-05-20

Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

15 enrolled

Hodgkin Disease

NCT03367741 2026-05-19

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

82 enrolled 11 charts

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT05136196 2026-05-19

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

150 enrolled

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05779423 2026-05-19

Cryoablation+Ipilimumab+Nivolumab in Melanoma

37 enrolled

Melanoma, Skin Neoplasms

NCT06029270 2026-05-19

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

156 enrolled

Nasopharyngeal Carcinoma

NCT04984733 2026-05-18

ELEVATE

Phase 2 Completed

13 enrolled

Esophageal Neoplasms, Neoplasms

NCT05034536 2026-05-18

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

36 enrolled

Melanoma

NCT05904080 2026-05-18

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

50 enrolled

Nasopharyngeal Carcinoma

NCT06365619 2026-05-18

NeoRelapse

25 enrolled

Melanoma

NCT06712927 2026-05-18

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

60 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT06863311 2026-05-18

EXACT

70 enrolled

Carcinoma, Renal Cell

NCT06948448 2026-05-18

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

144 enrolled

Colorectal Neoplasms

NCT02693535 2026-05-15

TAPUR

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT03134118 2026-05-15

NIVOTHYM

55 enrolled

DermatologicHead & NeckThoracic

Thymoma

NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Phase 2 Terminated

225 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04019964 2026-05-15

Nivolumab in Biochemically Recurrent dMMR Prostate Cancer

Phase 2 Completed

8 enrolled 12 charts

Prostatic Neoplasms

NCT05704647 2026-05-15

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

30 enrolled

Melanoma

NCT05846659 2026-05-15

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

Phase 2 Terminated

16 enrolled 13 charts

Oligoprogressive

NCT06015724 2026-05-15

DARANIVOVAX

54 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04042753 2026-05-14

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

9 enrolled

Endocrine

Pituitary Diseases, Pituitary Neoplasms

NCT04848116 2026-05-14

Spark2

24 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06946797 2026-05-14

CheckMate-1533

76 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07432295 2026-05-14

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

180 enrolled

Adenocarcinoma Of Esophagus, Neoplasm Metastasis, Stomach Neoplasms

NCT02834013 2026-05-13

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

818 enrolled

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT02978625 2026-05-13

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers